TrialBMC psychiatry2020

Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with attention-deficit/hyperactivity disorder.

Takuya Saito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.